1. Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.
- Author
-
Sinicrope, Frank A., Shi, Qian, Catteau, Aurelie, Poage, Graham M., Zemla, Tyler J., Mlecnik, Bernhard, Benson, Al B., Gill, Sharlene, Goldberg, Richard M., Kahlenberg, Morton S., Nair, Suresh G., Shields, Anthony F., Smyrk, Thomas C., Galon, Jerome, and Alberts, Steven R.
- Subjects
CLINICAL trials ,FLUOROURACIL ,LIKELIHOOD ratio tests ,FOLINIC acid ,OXALIPLATIN ,HEREDITARY nonpolyposis colorectal cancer - Abstract
PURPOSE: The recommended duration of adjuvant fluoropyrimidine and oxaliplatin chemotherapy for patients with stage III colon cancer is based on tumor classification into clinically low-risk (T
1-3 N1 ) and high-risk (T4 or N2 ) groups. We determined whether Immunoscore can enhance prognostication within these risk groups. MATERIALS AND METHODS: Patients with stage III colon carcinomas (N = 600) were randomly selected from the infusional fluorouracil, leucovorin, and oxaliplatin arm of adjuvant trial NCCTG N0147 (Alliance for Clinical Trials in Oncology). Tumors were evaluated for Immunoscore that quantifies CD3+ and CD8+ T-cell densities in the tumor center and invasive margin by digital image analysis. Disease-free survival (DFS) by Immunoscore was analyzed using a multivariable Cox regression model in each risk group with adjustment for covariates including KRAS , BRAFV600E , and mismatch repair status. RESULTS: Of 559 cancers with Immunoscore data, 299 (53.5%) were classified as clinically low-risk (T1-3 N1 ) and 260 (46.5%) as clinically high-risk (T4 and/or N2 ). Among patients with low-risk tumors, those with Immunoscore-Low versus Immunoscore-High tumors had significantly worse 5-year DFS rates (77.5% v 91.8%; hazard ratio, 1.70; 95% CI, 1.03 to 2.79; P =.037). Among patients with high-risk tumors, those with Immunoscore-Low versus Immunoscore-High tumors also had significantly worse DFS (55.3% v 70.3%; hazard ratio, 1.65; 95% CI, 1.11 to 2.47; P =.013). Tumors that were low-risk/Immunoscore-Low had similar outcomes as did tumors that were high-risk/Immunoscore-High (P =.174). Prognostication was significantly improved in multivariable models where Immunoscore was added to clinical risk parameters and limited biomarkers (likelihood ratio test P =.0003). CONCLUSION: Immunoscore can refine patient prognosis beyond clinical risk group classification, suggesting its potential utility for adjuvant decision making. Immunoscore can refine prognosis beyond clinical risk group classification in stage III colon cancer. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF